Back to Search Start Over

Accelerated DNA methylation age and medication use among African Americans

Authors :
Scott M. Ratliff
Wei Zhao
Patricia A. Peyser
Dima Chaar
Jennifer A. Smith
Yi Zhe Wang
Sharon L.R. Kardia
Thomas H. Mosley
Minjung Kho
Source :
Aging (Albany NY)
Publication Year :
2021
Publisher :
Impact Journals, LLC, 2021.

Abstract

DNA methylation age acceleration, the discrepancy between epigenetic age and chronological age, is associated with mortality and chronic diseases, including diabetes, hypertension, and hyperlipidemia. In this study, we investigate whether medications commonly used to treat these diseases in 15 drug categories are associated with four epigenetic age acceleration measures: HorvathAge acceleration (HorvathAA), HannumAge acceleration (HannumAA), PhenoAge acceleration, and GrimAge acceleration (GrimAA) using cross-sectional (Phase 1, N=1,100) and longitudinal (Phases 1 and 2, N=266) data from African Americans in the Genetic Epidemiology Network of Arteriopathy (GENOA) study. In cross-sectional analyses, the use of calcium channel blockers was associated with 1.27 years lower HannumAA after adjusting for covariates including hypertension (p=0.001). Longitudinal analyses showed that, compared to those who never used antihypertensives, those who started to take antihypertensives after Phase 1 had a 0.97-year decrease in GrimAA (p=0.007). In addition, compared to those who never used NSAID analgesics, those who started to take them after Phase 1 had a 2.61-year increase in HorvathAA (p=0.0005). Our study demonstrates that three commonly used medications are associated with DNAm age acceleration in African Americans and sheds light on the potential epigenetic effects of pharmaceuticals on aging at the cellular level.

Details

ISSN :
19454589
Volume :
13
Database :
OpenAIRE
Journal :
Aging
Accession number :
edsair.doi.dedup.....f811a24003aee7d9861384e81f339e5d
Full Text :
https://doi.org/10.18632/aging.203115